A working party of EU member state experts has welcomed proposals for a new cost-based approach to setting industry fees charged by the European Medicines Agency. However, it is concerned that the proposed fee levels for certain services will not cover the costs incurred by national regulatory agencies in providing these services.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?